Imatinib Sandoz

Imatinib, the active ingredient in Imatinib Sandoz, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It targets specific cancers such as chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor, providing a targeted therapeutic option for adult patients.

GNH USA supplies Imatinib Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for oncology therapeutics across global markets.

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways, making it a cornerstone therapy in several hematologic and solid‑tumor indications.

- Chronic myeloid leukemia (CML): improves disease control and prolongs survival by selectively inhibiting BCR‑ABL tyrosine‑kinase activity in leukemic cells. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): facilitates remission and reduces blast proliferation through targeted inhibition of the BCR‑ABL fusion protein. - Gastrointestinal stromal tumor (GIST): suppresses tumor growth and progression by blocking c‑KIT and platelet‑derived growth factor receptor (PDGFR) signaling pathways.

Imatinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: